as on November 3, 2025 at 10:37 pm IST
Day's Low
Day's High
1.68%
Downside
5.88%
Upside
52 Week's Low
52 Week's High
27.55%
Downside
217.65%
Upside
Check Allogene Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$275.1M
EPS (TTM)
-1.0256
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-1.97
Industry PE ratio
-0.8126129032258065
PEG Ratio
0EBITDA
-228.5M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-55.12%
Track how Allogene Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Allogene Therapeutics, Inc. in the last 5 years
Lowest (-18.43x)
March 31, 2021
Today (-1.97x)
November 3, 2025
Industry (-0.81x)
November 3, 2025
Highest (-1.20x)
June 30, 2025
Today’s Price to Earnings Ratio: -1.97x
Compare market cap, revenue, PE, and other key metrics of Allogene Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $275.1M | -96.33% | -1.97 | 0.00% | |
| BUY | $40.4B | 478.23% | -16.34 | -264.83% | |
| BUY | $60.2B | 253.38% | 1425.12 | 1.36% | |
| BUY | $109.1B | 101.56% | 30.31 | 31.86% | |
| BUY | $68.5B | 16.98% | 15.62 | 32.13% |
The Allogene Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Allogene Therapeutics, Inc. investment value today
Current value as on today
₹49,451
Returns
Returns from Allogene Therapeutics, Inc. Stock
Dollar Returns*
₹5,701 (+5.7%)
Based on 23 analysts
73.91%
Buy
26.09%
Hold
0.00%
Sell
Based on 23 analysts, 73.91% of analysts recommend a 'BUY' rating for Allogene Therapeutics, Inc.. Average target price of $7.56
Get share price movements and forecasts by analysts on Allogene Therapeutics, Inc..
What analysts predicted
84.26%UPSIDE
Target Price
$7.56
Current Price
$1.19
Analyzed by
23 Analysts
Target
$7.56
Allogene Therapeutics, Inc. target price $7.56, a slight upside of 84.26% compared to current price of $1.19. According to 23 analysts rating.
Search interest for Allogene Therapeutics, Inc. Stock has increased by 145% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:145% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
![]()
Netprofit is up for the last 5 quarters, -66.35M → -50.94M (in $), with an average increase of 7.1% per quarter
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 177.5% return, outperforming this stock by 231.9%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 958.0% return, outperforming this stock by 1045.0%
Price Dip
![]()
In the last 3 years, ALLO stock has moved down by -87.0%
Revenue Fall
![]()
Revenue is down for the last 2 quarters, 22.0K → -22.0K (in $), with an average decrease of 200.0% per quarter
| Organisation | Allogene Therapeutics, Inc. |
| Headquarters | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Industry | Health Technology |
| CEO | Dr. David D. Chang M.D., Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Susan R. Lundeen | Chief People Officer |
Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer |
Ms. Annie Yoshiyama | SVP & Corporate Controller |
Mr. Joshua A. Kazam | Co-Founder & Director |
Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer |
Mr. Geoffrey M. Parker | Executive VP & CFO |
Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer |
Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman |
Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director |
Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary |
Allogene Therapeutics, Inc. share price today is $1.19 as on . Allogene Therapeutics, Inc. share today touched a day high of $1.26 and a low of $1.17.
Allogene Therapeutics, Inc. share touched a 52 week high of $3.78 on and a 52 week low of $0.86 on . Allogene Therapeutics, Inc. stock price today i.e. is trending at $1.19,which is 68.52% down from its 52 week high and 38.04% up from its 52 week low.
Allogene Therapeutics, Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Allogene Therapeutics, Inc. (ALLO) shares with as little as ₹88.715 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.15 in Allogene Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Allogene Therapeutics, Inc. share’s latest price of $1.19 as on November 3, 2025 at 10:37 pm IST, you will get 8.4034 shares of Allogene Therapeutics, Inc.. Learn more about
fractional shares .
Allogene Therapeutics, Inc. stock has given -96.33% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?